이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Sacral Erector Spinae Plane Block for Catheter-Related Bladder Discomfort After HoLEP

2026년 11월 12일 업데이트: Kadriye Dıvrak, Ankara Etlik City Hospital

Evaluation of the Effect of Bilateral Sacral Erector Spinae Plane Block on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Holmium Laser Enucleation of the Prostate

Catheter-related bladder discomfort (CRBD) is common after holmium laser enucleation of the prostate (HoLEP). This single-center, randomized, controlled, assessor-blinded trial evaluates whether an ultrasound-guided bilateral sacral erector spinae plane (S-ESP) block performed before general anesthesia reduces the incidence of CRBD compared with general anesthesia alone in men aged 50 to 80 years undergoing elective HoLEP. The primary outcome is the incidence of CRBD at 1 hour after surgery.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Catheter-related bladder discomfort (CRBD) is a common and distressing postoperative symptom complex in male patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP), characterized by a suprapubic burning sensation, an urge to void, and involuntary bladder spasms due to three-way urinary catheterization and continuous bladder irrigation. The sacral erector spinae plane (S-ESP) block is an ultrasound-guided interfascial plane block that targets the S2-S4 sacral nerve roots, which provide both somatic (via the pudendal nerve) and visceral parasympathetic (via pelvic splanchnic nerves) innervation to the lower urinary tract. While current evidence regarding the efficacy of the S-ESP block against a no-block control group in HoLEP surgery is limited, blocking these sacral pathways may effectively modulate afferent bladder stimuli.

A total of 100 male patients aged 50 to 80 years with ASA physical status I-III scheduled for elective HoLEP surgery under general anesthesia will be randomly assigned in a 1:1 ratio to either the S-ESP block group (Group S, n=50) or the standard care control group (Group G, n=50) using computer-generated randomization and sealed opaque envelopes.

Patients in Group S will be placed in the prone position approximately 30 minutes before surgery under standard monitoring. Using a convex ultrasound transducer (GE HealthCare C1-5 probe) in a longitudinal paramedian orientation at the S2 intermediate sacral crest level, a 22G 80-100 mm echogenic block needle will be advanced in-plane in a craniocaudal direction into the fascial plane between the erector spinae aponeurosis and the sacral crest. Following hydrodissection with 1-2 mL normal saline and negative aspiration, 20 mL of 0.25% bupivacaine will be injected on each side (total 40 mL, 100 mg; not exceeding the maximum safe dose of 2 mg/kg). Sensory blockade will be assessed 30 minutes after block completion via pinprick testing over the bilateral S2-S4 dermatomes.

Both groups will receive a standardized general anesthesia protocol: induction with IV fentanyl (1 mcg/kg), propofol (2-2.5 mg/kg), and rocuronium (0.3 mg/kg) to facilitate laryngeal mask airway (LMA) insertion, followed by maintenance with 1 MAC sevoflurane and titrated remifentanil infusion (0.05-0.2 mcg/kg/min). Approximately 30 minutes before the end of surgery, all patients will receive IV paracetamol (1 g) and IV tramadol (100 mg) for multimodal analgesia, followed by routine postoperative IV paracetamol (1 g twice daily).

An independent anesthesiologist blinded to group allocation will assess postoperative outcomes at 30 minutes and at 1, 2, 4, 6, 12, and 24 hours. If the Visual Analog Scale (VAS) pain score is ≥4, IV tramadol (1 mg/kg, up to 400 mg/day) will be administered as rescue analgesia. If the CRBD score is ≥2 after excluding mechanical catheter obstruction, rescue antispasmodic or antimuscarinic medication will be administered. Quality of recovery will be evaluated at 24 hours using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T).

연구 유형

중재적

등록 (추정된)

100

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Derya Ozkan, Prof., MD
  • 전화번호: 00905425843638
  • 이메일: derya_z@yahoo.com

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

50년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • Male patients aged between 50 and 80 years
  • American Society of Anesthesiologists (ASA) physical status class I to III
  • Scheduled for elective Holmium Laser Enucleation of the Prostate (HoLEP) surgery under general anesthesia
  • Patients who agree to participate in the study and sign the written informed consent form

Exclusion Criteria:

  • Age under 50 years or over 80 years
  • ASA physical status class IV or higher
  • Known hypersensitivity or allergy to local anesthetics
  • History of chronic opioid use
  • Chronic pain syndrome
  • History of peripheral neuropathy, sacral neurological disease, or neurogenic bladder
  • Overactive bladder or prominent preoperative bladder irritation symptoms
  • History of previous prostate, bladder neck, or lower urinary tract surgery
  • Active urinary tract infection
  • Anticoagulant/antiplatelet use that contraindicates block administration according to current regional anesthesia guidelines, or clinically significant coagulopathy
  • Infection or severe dermatological lesion at the block application site
  • Severe renal failure (eGFR < 30 mL/min/1.73m2) or clinically significant hepatic failure
  • Cognitive impairment, communication difficulty, or psychiatric/neurological condition preventing postoperative assessments
  • Anticipated need for postoperative intensive care unit admission
  • Presence of a preoperative indwelling urinary catheter
  • Emergency surgery
  • Patient refusal or withdrawal of consent

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: S-ESPB Group

Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia.

Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia

활성 비교기: Standard Care Group

Standardized general anesthesia without any block or sham injection.

Standardized general anesthesia without any block.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of Catheter-Related Bladder Discomfort (CRBD) at Postoperative 1 Hour
기간: 1 hour after surgery

CRBD is graded on a 4-point scale: 0 = none; 1 = mild (reported only on questioning); 2 = moderate (reported spontaneously, without behavioral responses); 3 = severe (reported spontaneously with behavioral responses such as strong verbal response, flailing limbs or attempts to remove the catheter). Incidence is the proportion of patients with a score of 1 or higher.

1 hour after surgery

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence of CRBD at other time points
기간: 30 minutes and 2, 4, 6, 12 and 24 hours after surgery

Proportion of patients with CRBD score of 1 or higher

30 minutes and 2, 4, 6, 12 and 24 hours after surgery
Severity of CRBD
기간: 30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery

CRBD severity will be graded on a 4-point ordinal scale from 0 (none) to 3 (severe). Moderate-to-severe CRBD is defined as a score ≥2.

30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
Postoperative pain score
기간: 30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery

Postoperative pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst pain).

30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
Intraoperative remifentanil consumption
기간: Intraoperative period

Total amount of intraoperative remifentanil consumed, recorded in micrograms (mcg) and normalized to body weight and duration (mcg/kg/hour).

Intraoperative period
Total Postoperative Rescue Analgesic Consumption
기간: First 24 hours after surgery

Total intravenous tramadol dose in milligrams

First 24 hours after surgery
Time to First Rescue Analgesic Request
기간: First 24 hours after surgery

Minutes from end of surgery to first rescue tramadol dose

First 24 hours after surgery
Antispasmodic or antimuscarinic requirement
기간: First 24 hours after surgery

Proportion of patients requiring additional antispasmodic or antimuscarinic medication for persistent moderate-to-severe CRBD (score ≥2)

First 24 hours after surgery
Incidence of Postoperative Nausea and Vomiting (PONV) and Other Adverse Events
기간: First 24 hours after surgery

Number and percentage of participants experiencing postoperative nausea and vomiting (PONV) or any block- or anesthesia-related adverse events.

First 24 hours after surgery
Postoperative Quality of Recovery Score (QoR-15T)
기간: At 24 hours after surgery

Quality of recovery will be evaluated using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T). Total scores range from 0 to 150, with higher scores indicating better postoperative recovery quality.

At 24 hours after surgery

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Derya Ozkan, Prof., MD, Ankara Etlik City Hospital

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 19일

기본 완료 (추정된)

2027년 3월 16일

연구 완료 (추정된)

2027년 3월 31일

연구 등록 날짜

최초 제출

2026년 11월 12일

QC 기준을 충족하는 최초 제출

2026년 11월 12일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • AEŞH-EK-2026-180

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

All personal data will be anonymized and individual participant data will not be made publicly available in accordance with institutional ethics committee approval.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .